Prevention and management of drug resistant hepatitis B virus infections

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 9, 2012, Pages 1432-1440

  Wang, Cheng ^a   Fan, Rong ^a   Sun, Jian ^a   Hou, Jinlin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistant hepatitis B virus; Hepatitis B virus; Nucles(t)ide analogues

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; INCIDENCE; INFECTION PREVENTION; PRIORITY JOURNAL;

EID: 84865395346     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07198.x     Document Type: Article

References (105)

1. Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 2008; 359: 1486-500.
2. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J. Gastroenterol. Hepatol. 2009; 24: 346-53.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97-107.
4. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
5. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
6. Schiff ER, Lee SS, Chao YC etal. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2011; 9: 274-6.
7. Werle-Lapostolle B, Bowden S, Locarnini S etal. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
8. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-95.
9. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608 e1-2.
10. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132: 1574-85.
11. Lok AS, Zoulim F, Locarnini S etal. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
12. Hongthanakorn C, Chotiyaputta W, Oberhelman K etal. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53: 1854-63.
13. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol. Int. 2008; 2: 147-51.
14. Keeffe EB, Zeuzem S, Koff RS etal. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2007; 5: 890-7.
15. Liaw YF, Kao JH, Prratvisuth T, Chan HLY. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Liver Int. 2012; 6: 531-61.
16. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-61.
17. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther. 2007; 12: 355-62.
18. Villet S, Pichoud C, Billioud G etal. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J. Hepatol. 2008; 48: 747-55.
19. Delaney WET, Ray AS, Yang H etal. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 2006; 50: 2471-7.
20. Jenh AM, Pham PA. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev. Anti Infect. Ther. 2010; 8: 1079-92.
21. Yuen L, Ayres A, Littlejohn M, Edwards R, Locarnini S. Differences in the evolution of hepatitis B surface antigen of European and Asian HBV genotypes in the era of antiviral therapy. Poster presentation at: 46th European Association for the Study of the Liver (EASL 2011), Berlin, Germany, April 1, 2011. 2011.
22. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009; 49: 1158-65.
23. Snow-Lampart A, Chappell B, Curtis M etal. No resistance to tenofovir disoproxil fumarate detected after up to 144weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763-73.
24. Heathcote EJ, Marcellin P, Buti M etal. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-43.
25. Marcellin P, Heathcote EJ, Corsa A, Liu Y, Miller MD, Kitrinos KM. No detectable resistance to Tenofovir Disoproxil Fumarate (TDF) following up to 240weeks of treatment in patients with HBeAg+ and HBeAg- chronic hepatitis B virus infection. Hepatology 2011; 54: 480A.
26. Zeng G, Wang Z, Wen S etal. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J. Viral Hepat. 2005; 12: 609-17.
27. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-9.
28. Yuen LK, Ayres A, Littlejohn M etal. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res. 2007; 75: 64-74.
29. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin. Liver Dis. 2010; 14: 439-59.
30. Allen MI, Deslauriers M, Andrews CW etal. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
31. Angus P, Vaughan R, Xiong S etal. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
32. Villet S, Ollivet A, Pichoud C etal. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 2007; 46: 531-8.
33. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.
34. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1001-10.
35. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-88.
36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ etal. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 2003; 348: 800-7.
37. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ etal. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2673-81.
38. Liaw YF, Gane E, Leung N etal. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-95.
39. Gane EJ, Wang Y, Liaw YF etal. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int. 2011; 31: 676-84.
40. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ etal. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology 2006; 131: 1743-51.
41. Bristol-Myers Squibb. Safety and antiviral activity of Entecavir in subjects with chronic hepatitis B following monotherapy in other Entecavir trials. ClinicalTrials.gov. Website. Cited 25 Sep 2011. Available from URL: http://clinicaltrials.gov/ct2/show/study/NCT01438424?term=ENTECAVIR+901&rank=1&view=record.
42. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5years of therapy. Hepatology 2009; 49: 1503-14.
43. Marcellin P, Chang TT, Lim SG etal. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003; 348: 808-16.
44. Hou J, Yin YK, Xu D etal. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1year of a randomized, double-blind trial. Hepatology 2008; 47: 447-54.
45. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-20.
46. Patterson SJ, George J, Strasser SI etal. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247-54.
47. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
48. Lok AS, Lai CL, Leung N etal. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
49. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
50. Marcellin P, Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J. Hepatol. 2005; 43: 920-3.
51. Locarnini S, Hatzakis A, Heathcote J etal. Management of antiviral resistance in patients with chronic hepatitis B. Antivir. Ther. 2004; 9: 679-93.
52. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
53. Locarnini S. Molecular virology of hepatitis B virus. Semin. Liver Dis. 2004; 24 (Suppl. 1): 3-10.
54. Svicher V, Cento V, Salpini R etal. Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig. Liver Dis. 2011; 43: 975-83.
55. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48: 88-98.
56. Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir. Ther. 2010; 15: 471-5.
57. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir. Ther. 2008; 13: 875-9.
58. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J. Hepatol. 2010; 53: 348-56.
59. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-83.
60. Keeffe EB, Dieterich DT, Han SH etal. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 2008; 6: 1315-41; quiz 286.
61. Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update. J. Gastroenterol. Hepatol. 2011; 26: 829-35.
62. Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J. Viral Hepat. 2011; 18: e212-16.
63. Pawlotsky JM. EASL clinical practice guidelines. J. Hepatol. 2009; 50: 227-42.
64. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
65. Woo G, Tomlinson G, Nishikawa Y etal. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-29.
66. Zeng M, Mao Y, Yao G etal. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int. 2012; 32: 137-46.
67. Marcellin P, Heathcote EJ, Buti M etal. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008; 359: 2442-55.
68. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-63.
69. Sung JJ, Lai JY, Zeuzem S etal. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol. 2008; 48: 728-35.
70. Yatsuji H, Suzuki F, Sezaki H etal. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: 2-year follow-up. J. Hepatol. 2008; 48: 923-31.
71. Zoutendijk R, Reijnders JG, Brown A etal. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443-51.
72. Karino Y, Toyota J, Kumada H etal. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol. Int. 2010; 4: 414-22.
73. Marcellin P, Chang TT, Lim SG etal. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-8.
74. Tenney D, Pokornowski K, Rose R, Baldick BJ. Entecavir maintains a high genetic barrier to HBV resistance through 6years in naïve patients. J. Hepatol. 2009; 50: S10.
75. Yuen MF, Seto WK, Chow DH etal. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther. 2007; 12: 1295-303.
76. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-8.
77. Lai CL, Leung N, Teo EK etal. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36.
78. Wang LC, Chen EQ, Cao J etal. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol. Int. 2011; 5: 671-6.
79. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
80. Lindh M, Hannoun C. Dynamic range and reproducibility of hepatitis B virus (HBV) DNA detection and quantification by Cobas Taqman HBV, a real-time semiautomated assay. J. Clin. Microbiol. 2005; 43: 4251-4.
81. Gane EJ. The roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol. Int. 2008; 2: 304-7.
82. Chien RN. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective. J. Gastroenterol. Hepatol. 2010; 25: 852-7.
83. Holness G, Carriero DC, Dieterich DT. Hepatitis B therapies and antiviral resistance detection and management. Expert Rev. Gastroenterol. Hepatol. 2009; 3: 693-9.
84. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J. Virol. 2009; 83: 1718-26.
85. Wong VW, Wong GL, Tse CH etal. Antiviral drug resistance testing in patients with chronic hepatitis B. Dig. Dis. Sci. 2012; 57: 221-31.
86. Wai CT, Wong ML, Ng S etal. Utility of the Health Belief Model in predicting compliance of screening in patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 2005; 21: 1255-62.
87. Westland CE, Yang H, Delaney WET etal. Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. J. Viral Hepat. 2005; 12: 67-73.
88. Inoue J, Ueno Y, Wakui Y etal. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J. Viral Hepat. 2011; 18: 206-15.
89. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WET. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir. Ther. 2005; 10: 625-33.
90. van Bommel F, de Man RA, Wedemeyer H etal. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
91. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 2008; 48: 391-8.
92. Lui YY, Tsoi KK, Wong VW etal. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir. Ther. 2010; 15: 145-55.
93. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-19.
94. Cassino L, Benetti S, Fay F, Tanno H, Quarleri J. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect. Dis. 2011; 11: 178-84.
95. Lange CM, Bojunga J, Hofmann WP etal. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-6.
96. Piratvisuth T, Lau G, Chao YC etal. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol. Int. 2008; 2: 102-10.
97. Shim JH, Lee HC, Kim KM etal. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J. Hepatol. 2010; 52: 176-82.
98. Lok AS. Drug therapy: tenofovir. Hepatology 2010; 52: 743-7.
99. Janssen HL, van Zonneveld M, Senturk H etal. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
100. Sarin SK, Sood A, Kumar M etal. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102: 96-104.
101. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med 2005; 352: 2682-95.
102. Sun J, Hou JL, Xie Q etal. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment. Pharmacol. Ther. 2011; 34: 424-31.
103. Marcellin P, Boyer N, Piratvisuth T, Tanwandee T, Pooi Huat T. Efficacy and safety of peginterferon Alpha-2a (40KD) (Pegasys) in patients with chronic hepatitis B who had received prior treatment with nucleos(t)ide analogues-The PEGALAM cohort. J. Hepatol. 2006; 44: S187.
104. Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver Int. 2010; 30: 657-68.
105. Gao LM, Han YX, Wang YP etal. Design and synthesis of oxymatrine analogues overcoming drug resistance in hepatitis B virus through targeting host heat stress cognate 70. J. Med. Chem. 2011; 54: 869-76.